CAMP

CAMP4 Therapeutics Corp. 10-Q Summary

Business Context and Reporting Period

CAMP4 Therapeutics Corp. is a clinical-stage biopharmaceutical company developing RNA-targeting therapeutics to treat genetic diseases, primarily focusing on the central nervous system. The company's lead candidate, CMP-002, targets SYNGAP1-related disorder. This report covers the quarterly period ended June 30, 2026. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.

Key Financial Metrics

Note: Revenue consists entirely of research and collaboration revenue. The company has no product sales.

Material Changes vs. Prior Period

• Net Loss Increase: Net loss for the six months ended June 30, 2026, increased to $51.9 million from $25.0 million in the prior year period. This increase was primarily driven by a $27.1 million non-cash expense related to the change in fair value of a derivative tranche liability associated with a private placement.
• Revenue Growth: Revenue increased by approximately 30% to $3.1 million, driven by a new collaboration agreement with GlaxoSmithKline (GSK) signed in December 2025, which included a $17.5 million upfront payment.
• Operating Expenses: Total operating expenses rose to $29.5 million from $28.5 million. Research and Development (R&D) expenses increased by $0.5 million due to higher personnel costs (including stock-based compensation) and clinical/preclinical costs for CMP-002. General and Administrative (G&A) expenses increased by $0.6 million, largely due to personnel costs.
• Liquidity: Cash and cash equivalents decreased by $23.7 million during the period due to operating losses, though the balance remains significantly higher than the prior year due to capital raises in late 2025.

Guidance, Outlook, and Risks

• Clinical Progress: The company received regulatory clearance in Australia and Argentina to initiate a Phase 1/2 clinical trial for CMP-002. The company intends to initiate the trial in the fourth quarter of 2026.
• Capital Resources: As of June 30, 2026, the company held $86.4 million in cash. Management estimates that this, combined with net proceeds of approximately $46.9 million from the "Second Closing" of a private placement (which occurred on August 3, 2026, subsequent to the reporting period), will fund operations through the end of 2028.
• Derivative Liability Settlement: The derivative tranche liability of $71.9 million recorded on the balance sheet was settled on August 3, 2026, in connection with the Second Closing of the private placement, generating gross proceeds of approximately $50.1 million.
• Risks: The company faces significant risks related to the need for additional capital, the uncertainty of clinical trial outcomes, and the timeline for regulatory approval. There are no approved products, and the company expects to incur losses for the foreseeable future.

Investor Verification Checklist

• Derivative Liability Impact: Verify the accounting treatment and cash impact of the $71.9 million derivative liability settlement that occurred in August 2026, as this significantly altered the company's capital structure post-reporting period.
• Cash Runway: Confirm the updated cash runway estimate of "through the end of 2028" based on the inclusion of the $46.9 million Second Closing proceeds.
• GSK Agreement Terms: Review the specific milestones and royalty structures of the GSK agreement, which provided the majority of recent revenue but includes significant variable consideration that is currently constrained.
• Clinical Trial Initiation: Monitor the actual start date of the Phase 1/2 trial for CMP-002, currently targeted for Q4 2026, as delays could impact future funding needs.
• Stock-Based Compensation: Note the increasing trend in stock-based compensation ($3.4 million for the six months ended June 2026 vs. $1.9 million in the prior year), which impacts future expense projections.